After having shown promising safety and efficacy in phase I and II clinical trials in treatment of patients with advanced-stage ALK- or ROS1-positive NSCLC [72], lorlatinib was approved for the treatment of pre-treated, advanced, ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.